# Tetra Pharm Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tetra-pharm-technologies-aps

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.tetra-pharm.com
- Total disclosed funding: $9.8M
- Latest round: Series A (Jan 26, 2023)
- Investors on record: 5

## About

Based in Copenhagen, Denmark, and founded in 2018, Tetra Pharm Technologies ApS operates as a research-focused biopharmaceutical company delivering cannabinoid-based therapies. As of January 2023, Martin Rose serves as the CEO of the company. In January 2023, Tetra Pharm Technologies raised EUR 9 million in Series A funding from Enexis AB, Leafy Tunnel, Nesroht Holding, Ole GS Holding, and Rump Invest.

The company offers therapeutic development for the ECS, GMP manufacture of commercial pharmaceuticals, and CDMO services and partnerships. The firm's objectives include researching potential new drugs, creating, and perfecting fresh drug formulations, conducting clinical studies, and commercialising drugs that target the endocannabinoid system.

The organization plans to use the January 2023 funding to increase its capacity in research and development and expand its commercial operations internationally.

## Funding rounds

- Series A, Jan 26, 2023, $9.8M — Enexis AB, Leafy Tunnel, Rump Invest, Nesroht Holding, Ole GS Holding

## Investors

- Enexis AB (https://capitalatlas.ai/funds/enexis-ab) — Series A
- Leafy Tunnel (https://capitalatlas.ai/funds/leafy-tunnel) — Series A
- Rump Invest — Series A
- Nesroht Holding — Series A
- Ole GS Holding — Series A